STOCK TITAN

John Paul DeJoria holds 9.4% of Telomir (TELO) common stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. shareholder John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust and in his individual capacity, reports beneficial ownership of 3,245,000 shares of common stock, representing 9.438% of the class. He has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Telomir, indicating a passive investment intent under the Schedule 13G framework.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
Signature:/s/ Matthew R. Bair
Name/Title:Matthew R. Bair, Attorney-in-Fact
Date:02/12/2026
Exhibit Information

EXHIBIT 24.1 Power of Attorney for John Paul DeJoria (Incorporated by reference).

FAQ

What ownership stake does John Paul DeJoria report in Telomir (TELO)?

John Paul DeJoria reports beneficial ownership of 3,245,000 Telomir shares, representing 9.438% of the company’s common stock. This sizeable stake gives him notable exposure to Telomir while remaining below typical 10% thresholds that can trigger additional regulatory obligations.

Does John Paul DeJoria have sole voting power over his Telomir (TELO) shares?

Yes, he has sole voting power over 3,245,000 shares and reports no shared voting power. He also has sole dispositive power over the same number of shares, meaning he alone can decide how these shares are voted and whether they are sold.

Is John Paul DeJoria’s Telomir (TELO) stake intended to influence control of the company?

The filing states the securities were not acquired or held to change or influence control of Telomir. This language aligns with a passive investment approach under Schedule 13G rather than an activist or control-seeking position.

What percentage of Telomir (TELO) does 3,245,000 shares represent?

The filing reports that 3,245,000 Telomir common shares represent 9.438% of the class. This indicates a significant but minority holding, giving economic and voting influence without crossing typical 10% insider thresholds.

In what capacity is John Paul DeJoria reporting his Telomir (TELO) holdings?

He reports in a dual capacity as trustee of the John Paul DeJoria Family Trust and in his individual capacity. Together, these positions account for the disclosed 3,245,000 Telomir common shares beneficially owned.

What type of securities does John Paul DeJoria hold in Telomir (TELO)?

The filing identifies the securities as Telomir Pharmaceuticals, Inc. common stock, no par value, with CUSIP 87975F104. All ownership, voting power, and dispositive power figures in the filing relate to this class of common shares.
Telomir Pharms

NASDAQ:TELO

TELO Rankings

TELO Latest News

TELO Latest SEC Filings

TELO Stock Data

37.48M
18.92M
31.5%
8.76%
9.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI